Asthma/COPD Stepwise Therapy — Stepwise therapy concepts for asthma/COPD (overview)

Historical Context & Motivation

Before standardized treatment guidelines existed, clinicians managed asthma and chronic obstructive pulmonary disease (COPD) largely through empirical trial and error, often resulting in under-treatment of inflammation or excessive reliance on bronchodilators. The concept of stepwise therapy arose from the recognition that both asthma and COPD are heterogeneous diseases whose severity fluctuates over time, requiring a dynamic, adaptable pharmacological approach rather than a static prescription. The development of stepwise frameworks was driven by mounting epidemiological evidence linking poorly controlled airway disease to preventable morbidity and mortality, particularly in the latter decades of the twentieth century.

The central question these frameworks address is both clinical and pharmacological: How do we select, combine, and titrate respiratory medications to achieve optimal disease control while minimizing adverse effects? The stepwise model provides a structured answer by matching therapeutic intensity to disease severity and patient response, enabling clinicians to step up therapy when control deteriorates and step down when stability is achieved.

Core Principles of Stepwise Therapy

Stepwise therapy is grounded in several interrelated pharmacological and clinical principles that distinguish it from empirical prescribing. Understanding these principles is essential for applying guideline-directed therapy appropriately across the spectrum of obstructive airway diseases.

Asthma Stepwise Therapy — Visual Overview

The diagram above encapsulates the fundamental logic of asthma stepwise management. At Step 1, patients with intermittent symptoms use only as-needed reliever therapy. As disease severity increases through Steps 2–4, daily controller medications are introduced and progressively intensified — first low-dose inhaled corticosteroids (ICS) alone, then ICS combined with a long-acting beta₂-agonist (LABA), and subsequently at higher ICS doses with or without a long-acting muscarinic antagonist (LAMA). At Step 5, phenotype-specific biologic therapies targeting IgE, interleukin-5, interleukin-4/13, or thymic stromal lymphopoietin (TSLP) are added for patients with refractory severe disease.

Pharmacological Mechanisms Underlying Each Step

Understanding why specific drug classes occupy particular positions in the stepwise hierarchy requires knowledge of the pathophysiological targets they address and their dose-response characteristics. The following sections detail the mechanism of action for each major drug class used in stepwise asthma and COPD therapy.

Inhaled Corticosteroids (ICS)

Inhaled corticosteroids remain the cornerstone of controller therapy in asthma. They bind intracellular glucocorticoid receptors (GR), translocate to the nucleus, and modulate gene transcription through two primary mechanisms: transactivation (upregulating anti-inflammatory proteins such as lipocortin-1 and IκB) and transrepression (suppressing pro-inflammatory transcription factors such as NF-κB and AP-1). The net effect is a reduction in airway eosinophilic infiltration, mucus hypersecretion, and bronchial hyperresponsiveness. The dose-response curve for ICS is relatively flat at higher doses, meaning that doubling the ICS dose yields diminishing incremental benefit while increasing the risk of systemic adverse effects such as adrenal suppression and osteoporosis.

Long-Acting Beta₂-Agonists (LABA)

LABAs such as salmeterol and formoterol stimulate β₂-adrenergic receptors on airway smooth muscle cells, activating adenylyl cyclase and increasing intracellular cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which phosphorylates myosin light chain kinase, reducing its affinity for calcium-calmodulin complexes and producing sustained smooth muscle relaxation lasting 12 hours or more. In asthma, LABAs should never be used as monotherapy due to an associated increase in serious asthma events; they are always combined with an ICS.

Long-Acting Muscarinic Antagonists (LAMA)

LAMAs such as tiotropium and umeclidinium competitively block muscarinic M₃ receptors on airway smooth muscle, preventing acetylcholine-mediated bronchoconstriction. They dissociate slowly from M₃ receptors, providing a prolonged duration of action (≥24 hours for tiotropium). LAMAs are a mainstay of COPD therapy and have been incorporated into asthma guidelines as add-on therapy at Steps 4–5 when ICS-LABA alone is insufficient.

Biologic Agents

Biologic therapies target specific inflammatory mediators in the type 2 (T2) immune pathway. Omalizumab binds free IgE, preventing its attachment to FcεRI on mast cells and basophils. Mepolizumab and benralizumab target IL-5 or its receptor, depleting eosinophils. Dupilumab blocks the IL-4Rα subunit shared by IL-4 and IL-13 receptors, broadly suppressing T2 inflammation. Tezepelumab targets TSLP, an upstream epithelial alarmin, and is the first biologic effective regardless of T2 biomarker status. These agents are reserved for Step 5 of asthma therapy due to their high cost and injectable administration.

COPD Stepwise Therapy — GOLD Framework

While the asthma stepwise model is organized around inflammation severity and ICS dose escalation, the GOLD framework for COPD uses a different organizing principle based on the ABCD assessment tool (updated to ABE in GOLD 2023). This system classifies patients along two axes: symptom burden (assessed by CAT or mMRC dyspnea score) and exacerbation history. Unlike asthma, the cornerstone of COPD pharmacotherapy is bronchodilation rather than anti-inflammatory therapy, because COPD involves fixed airflow limitation driven primarily by structural changes (emphysema, small airway fibrosis) rather than purely reversible bronchoconstriction.

A critical distinction between the asthma and COPD stepwise models is the role of ICS. In asthma, ICS is introduced early (Step 2) and forms the foundation of therapy. In COPD, ICS is added selectively — primarily in patients with blood eosinophil counts ≥300 cells/μL who continue to experience exacerbations despite dual bronchodilation (LABA + LAMA). This eosinophil-guided approach reflects the understanding that only a subset of COPD patients — those with eosinophilic inflammation — derive meaningful benefit from ICS, while others face an increased risk of pneumonia without commensurate exacerbation reduction.

Worked Example — Applying Stepwise Therapy to a Patient Case

The following case illustrates how stepwise therapy principles guide clinical decision-making in a patient with asthma whose disease control is deteriorating.

Strengths and Limitations of Stepwise Models

Stepwise therapy frameworks have dramatically improved the standardization and quality of respiratory care, but they are not without limitations. A critical appraisal of these models helps clinicians use them wisely rather than rigidly.

Connection to Advanced Respiratory Pharmacotherapy

Stepwise therapy as presented in introductory pharmacology courses represents the foundational framework, but advanced respiratory pharmacotherapy extends these concepts into precision medicine, pharmacogenomics, and novel therapeutic modalities. Understanding these connections prepares healthcare students for the evolving landscape of obstructive airway disease management.

The broader trajectory of respiratory pharmacology is moving toward a precision medicine paradigm where therapy is individualized based on molecular endotyping rather than clinical phenotyping alone. The stepwise framework will likely evolve to incorporate computational tools — such as machine learning algorithms analyzing electronic health record data, spirometric trends, and multi-omics profiles — to generate personalized treatment pathways. For now, mastery of the current stepwise models provides the essential scaffolding upon which these advanced concepts are built.

Practice Problems

Lesson Summary